Evidence map›Paper›PMID 42645801›Full record

ArticleInfectious disease reports2026

Early Machine Learning-Based Identification of Hospitalized Patients at Low Risk of Respiratory Deterioration or Mortality in Community-Acquired Pneumonia: External Validation of a Multivariable Model.

Claudia Gyimah, Prasamsa Pudasaini, Allison LeMahieu, Phillip Schulte, Yewande E Odeyemi

Abstract read
In one paragraph

Article in Infectious disease reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Claudia GyimahDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.ORCID 0009-0005-3158-8630
Prasamsa PudasainiDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Allison LeMahieuDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-1554-795X
Phillip SchulteDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA.
Yewande E OdeyemiDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.ORCID 0000-0002-4446-198X

Funding

Pragmatic trial of midodrine as a vasopressor-sparing agent in septic shockR61HL177037 · NHLBI · MAYO CLINIC ROCHESTER · PI GAJIC, OGNJEN · 2025 to 2025
$784k
Individualizing Steroid Use in Pneumonia (Supplement)K23HL168212 · NHLBI · MAYO CLINIC ROCHESTER · PI Yewande Odeyemi · 2023 to 2026
$751k
NHLBI NIH HHS K23 HL168212NHLBI NIH HHS R61 HL177037NIH HHS 1K23HL168212-03
6 · The paper itself

Abstract

BACKGROUND/

objectiveTo externally validate our previously published machine learning model for identifying hospitalized patients with community-acquired pneumonia (CAP) at low risk of respiratory deterioration or death using the Medical Information Mart for Intensive Care IV (MIMIC-IV) database.

methodsThis is a retrospective cohort study of adult patients (≥18 years) who were admitted with CAP and acute hypoxemic respiratory failure using the publicly available MIMIC-IV critical care dataset (Beth Israel Deaconess Medical Center, Boston, MA). We conducted an external validation study of a previously developed gradient boosting machine (GBM) model without recalibration using data available within the first 6 h of hospital admission.

resultsFor the primary composite outcome (need for advanced respiratory support [high flow nasal cannula (HFNC), non-invasive mechanical ventilation (NIMV), invasive mechanical ventilation (IMV)] or in-hospital death), the gradient boosting model demonstrated comparable performance in the derivation and external validation cohorts. The area under the receiver operating characteristic curve (AUC) was 0.713 in the Mayo cohort (n = 4379) and 0.689 in the MIMIC-IV cohort. Accuracy was 0.612 (95% confidence interval [CI], 0.595-0.628) versus 0.606 (95% CI 0.600-0.611), specificity 0.574 versus 0.523, sensitivity 0.723 versus 0.754, NPV 0.860 versus 0.842, and PPV 0.364 versus 0.401, respectively. For secondary outcomes, model discrimination was comparable between cohorts. The AUC for in-hospital mortality was 0.727 in the Mayo Cohort versus 0.733 in MIMIC-IV; for IMV, 0.736 versus 0.724; and for NIMV, 0.732 versus 0.708.

conclusionsOur machine learning algorithm demonstrated good discrimination and a high negative predictive value for identifying low-risk hospitalized CAP patients for respiratory deterioration or death in the external MIMIC-IV dataset, supporting its potential utility for prognostic enrichment in pneumonia clinical trials.

Indexed as

and mortalitycommunity-acquired pneumoniahospitalized patientsmachine learning modelsrespiratory deterioration

Identifiers

PMID42645801
PMCPMC13512326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.